Recursion Pharmaceuticals (NASDAQ: RXRX)
Recursion Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Recursion Pharmaceuticals Company Info
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
News & Analysis
Where Will Recursion Pharmaceuticals Be in 5 Years?
A lot is riding on whether its platform is valuable, or vaporware.
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Recursion is playing the long game with its AI-focused approach to drug discovery and development.
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
This stock's upside is huge, but so is its downside.
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
The company just made a provocative move in one of its collaborations.
Why Recursion Pharmaceuticals Stock Dived by Nearly 17% Today
The company had attracted much interest due to its heavy use of artificial intelligence, but its latest fundamentals disappointed many.
Why Recursion Pharmaceuticals Stock Zoomed Higher on Thursday
A top name in the artificial intelligence world has put its money where its mouth is with this biotech.
2 Cathie Wood Stocks With Jaw-Dropping Growth Potential
These two platform biotechs could revolutionize the field of biologically based products.
Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.
Scaling up means having more power to bring to bear on core activities.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.